International Journal of Medical and All Body Health Research  |  e-ISSN: 2582-8940  |  Double-Blind Peer Review  |  Open Access  |  CC BY-NC-SA 4.0

Current Issues
     2026:7/4

International Journal of Medical and All Body Health Research

e-ISSN: 2582-8940 | Open Access

An Innovative Approach of Escalating Maternal Fetal Outcomes in Pregnancies associated with Obesity: Overcoming Deficiency of Resolvins associated with Obesity: A Systematic Review

Article Information

Volume / Issue3 / 4 (October-December 2022)
Pages03-13
AccessOpen Access

Publication Timeline

  • Received25 September 2022
  • Accepted11 October 2022

Full Text (PDF)

Open Access - Free to Download

Download Full Article (PDF) JATS XML

Abstract

In view of pregnancy possessing the properties of mild however considerable significant inflammatory action under physiological circumstances, ongetting complicated byobesity the chances of a continuous inflammatory state enhances with subsequent numerous consequences with additional complications correlated with acute inflammation. Regarding this the part of resolvins alias Specialized proresolving mediators (SPM) obtained from Omega3 essentiafatty acids might bekey. Actually differential generation of multiple high risk situations is correlated with child birth along with neonatal health, the association amongst, maternal omega 3 fatty acids consumption as well as resolvins amounts in maternal blood along with placental level in addition to greater amounts observed in breast milk at the time of first mth of breast feeding, represent certain of the maximum significant cornerstone concerning these autacoids. In addition to that escalation of scientific corroboration proves the absence of SPM at the immuno metabolic tissue level regarding obesity. Moreover, the obesity correlated absence of SPMs apparently is the deciding factor even regarding the recent Coronavirus disease (COVID19) pandemic since apparently it is amongst the reasons correlated with greater complications in addition to the negative results of SARS-CoV2 infection. The utilization of metabolomics in this speciality has been clarified, with the information that via metabolome it is feasible to watch the multiple along with complicated crosstalk amongst mother, placenta along with fetus, regarding the Identification of particular biomarker regarding the anticipation, diagnosis besides supervision of different obstetric situations. Nevertheless, greater evaluation is required for part of resolving as biomarkers of Maternal –Fetal outcomes besides generation of enough values regarding integration in pregnant women with Omega3 fatty acids or with greater derivatives for ensuring ideal SPM generation under high risk situations.

 

References

  1. Poon LC, McIntyre HD, Hyett JA, da Fonseca EB, Hod M. FIGO Pregnancy and NCD Committee. The first trimester of Pregnancy-a WINDOW of opportunity of pregnancy complications and future life. Diabetes Res Clin Pract. 2018; 145:20-30. [Google Scholar][Crossref]
  2. Parrettini S, Carroli A, Torlone E. Nutrition and metabolic adaptations in physiological and complicated pregnancy: focus on obesity and Gestational Diabetes. Front Endocrinol. 2020; 11:6111929. [Google Scholar][Crossref]
  3. Chen C, Xu X, Yan Y. Estimated global over weight and obesity burden in pregnant women based on panel data model. PLoS. ONE2018:13:e0202183. [Google Scholar][Crossref]
  4. Robinson E, Boyland E, Chrisholm A, Harrold J, Maloney NG, Marty L, et al. Obesity, eating behaviour and physical activity during Covid19 lockdown: a study of UK adults. Appetite. 2021; 156:104853. [Google Scholar][Crossref]
  5. Ghesquiere L, Garabedian C, Drumez E, Lemaltre M, Cazaubiel M, Bengler C, et al. Effects of Covid19 pandemic lockdown on Gestational Diabetes mellitus: a retrospective study. Diabetes Metab. 2021; 47:101201. [Google Scholar][Crossref]
  6. Zhang J, Zhang Y, Huo S, Ma Y, Ke Y, Wang P, et al. Emotional eating in pregnant women during COVID19 pandemic and its association with dietary intake and gestational weight gain. Nutrients. 2020; 12:2250. [Google Scholar][Crossref]
  7. Elliot E, Hanson CK, Anderse-Berry AL, Nordgren TM. The role of specialized pro resolving mediators in maternal fetal health. Prostaglandins Leukot Essent Fat Acids. 2017; 126:98-104. [Google Scholar][Crossref]
  8. Hulzinga GP, Singer BH, Singer K. The collision of meta inflammation and SARS-CoV2 pandemic infection. Endocrinology. 2020; 161:bqaa154. [Google Scholar][Crossref]
  9. Dalamaga M, Christodoulatos GS, Karampela I, Vallianou N, Apovian CM. Understanding the co-epidemic of obesity and Covid19: current evidence with previous epidemics, mechanisms and preventive and therapeutic perspectives. Curr Obese Rep. 2021; 10:214-43. [Google Scholar][Crossref]
  10. Tognocchi M, Conte M, Testai L, Martucci M, Serra A, Calderone V, et al. Supplementation of enriched polyunsaturated fatty acids and CLA cheese on high fat diet: Effects on lipids metabolism and fat profile. Foods. 2022; 11:398. [Google Scholar][Crossref]
  11. Strunk T, Inder T, Wang X, Brugner D, Mallard C, Levy O. Infection induced inflammation and cerebral injury in preterm infants. Lancet Infect Dis. 2014; 14:751-62. [Google Scholar][Crossref]
  12. Koletzko B, Boey CC, Campoy C, Carlson SE, Chang N, Guillermo Tuazon M, et al. Current information and Asian perspectives on long chain polyunsaturated fatty acids in pregnancy, lactation and infancy: systematic International Journal of Medical and All Body Health Research www.allmedicaljournal.com review and Practice recommendations from an early nutrition academy workshop. Ann Nutr Metab. 2014; 65:49-80. [Google Scholar][Crossref]
  13. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Rev Immunol. 2005; 6:1191-7. [Google Scholar][Crossref]
  14. Willoughby DA, Moore AR, Colville-Nash PR, Gillroy D. Resolution of inflammation. Int J Immunopharmacol. 2000; 22:1131-5. [Google Scholar][Crossref]
  15. Han J, Ulevitch RJ. Limiting inflammatory responses during activation of innate immunity. Nat Rev Immunol. 2005; 6:1198-205. [Google Scholar][Crossref]
  16. Tracy KJ. Physiology and Immunology of cholinergic anti inflammatory pathway. J Clin Investig. 2007; 117:289-96. [Google Scholar][Crossref]
  17. Kulvinder Kochar Kaur, Allahbadia GN, Singh M. A Review of Nutrient Metabolism in Obesity with Special Emphasis on Fatty Acid Metabolism. BAOJ Food Sci& Tec, 1, 001. [Google Scholar][Crossref]
  18. Kulvinder Kochar Kaur, Allahbadia GN, Singh M. Synthesis and functional significance of Poly Unsaturated fatty acids (PUFA’s) in body. Acta Scientific Nutritional Health. 2018; 2(4):43-50. [Google Scholar][Crossref]
  19. Kulvinder Kochar Kaur, Allahbadia GN, Singh M. The association of dietary fatty acids and gut microbiota alterations in the development of neuropsychiatric diseases: A systematic review. Obes Res Open J. 2020; 7(1):19-45. Doi: 10.17140/OROJ-7-143. [Google Scholar][Crossref]
  20. Chiang N, Serhan CN. Specialized pro resolving mediators networks: an update on production and actions. Essays Biochem. 2020; 64:443-62. [Google Scholar][Crossref]
  21. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Investig. 2011; 121:2111-17. [Google Scholar][Crossref]
  22. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011; 29:415-45. [Google Scholar][Crossref]
  23. Spite M, Claria J, Serhan CN. Resolvins, specialized proresolving mediators, and their potentialroles in metabolic diseases. Cell Metab. 2014; 19:21-36. [Google Scholar][Crossref]
  24. Chawla A, Nguyen KD, Goh YP. Macrophage Mediated inflammation in metabolic diseases. Nat Rev Immunol. 2011; 11:85-97. [Google Scholar][Crossref]
  25. Evan’s AC, Papachristou GI, Whitcomb DC. Obesity and the risk of severe acute Pancreatitis. Minerva Gastroenterol Dietol. 2010; 56:169-79. [Google Scholar][Crossref]
  26. Elias CF, Aschkenasi C, Lee C, Kelly J, Ahima RS, Bjorbaek C, et al. Leptin differentially regulates NPY and POMC neurons projecting to the lateral hypothalamic area. Neuron. 1999; 23:775-86. [Google Scholar][Crossref]
  27. Serhan CN. Resolution phase of inflammation: novel anti-inflammatory and pro resolving mediators and pathways. Annu Rev Immunol. 2007; 25:101-37. [Google Scholar][Crossref]
  28. Serhan CN, Yacoubian S, Yang R. Anti inflammatory and proresolving mediators. Annu Rev Pathol 2008; 3:279-312. [Google Scholar][Crossref]
  29. Bannenberg G, Serhan CN. Specialized pro resolving mediators in the inflammatory responses. Biochim Biophys Acta. 2010; 1801:1260 73. [Google Scholar][Crossref]
  30. Mozurkewicz EL, Greenwood M, Clinton C, Berman D, Romero V, Djuric Z, et al. Pathway markers for proresolving lipids mediators in maternal and cord blood: a secondaryanalysis of mothers, Omega3 along with Mental Health study. Front Pharmacol. 2016; 7:274. [Google Scholar][Crossref]
  31. Videla LA, Vargas R, Valenzuela R, Munoz P, Corbari A, Hernandez-Rodas MC. Combined administration of docosahexaenoic acid and the thyroid hormone synergistically rat liver cells of resolvins RvD1 and RvD2. Prostaglandins Leukot Essent Fat Acids. 2019; 140:42-6. [Google Scholar][Crossref]
  32. Li C, Wu X, Liu S, Shen D, Zhu J, Liu K. Role of Resolvins in the inflammatory Resolution of neurological diseases. Front Pharmacol. 2020; 11:612 [Google Scholar][Crossref]
  33. Ostermann AL, West AL, Schoenfeld K, Browning LM, Walker CC, Jebb SA, et al. Plasma oxilipins respond to a linear dose response manner with increased intake of EPA and DHA: results from a randomized controlled Clinical trial in healthy humans. Am J Clin Nutr. 2019; 109:1251-63. [Google Scholar][Crossref]
  34. Isobe Y, Arita M, Matsueda S, Iwamoto R, Fujihara T, Nakahashi H, et al. Identification and structure determination of novel anti inflammatory mediator resolvin E3,17,18 di hydroxy eicosapentaenoic acid. JBiol Chem. 2012; 287:10525-34. [Google Scholar][Crossref]
  35. Bosco A, Dessi A, Zanza C, Pintus R, Fanos V. Resolvin‘s Obesity driven deficiency: the implications for Maternal Fetal health. Nutrients. 2022; 14:1662. [Google Scholar][Crossref]
  36. Valdes AM, Ravipatti S, Menni C, Abishek A, Metrustry A, Harris J, et al. Association of the resolvin precursors 17HDHA butnot D or E series resolvins with heat pain sensitivity and osteoarthritis pain in humans. Sci Rep. 2017; 7:10748. [Google Scholar][Crossref]
  37. Mas E, Croft KD, Zahra P, Barden A, Mori TA. Resolvins D1, D2 and other mediators of self-limited Resolution of inflammation in human blood following n-3 fatty acids Supplementation. Clin Chem 2012; 58:1476-84. [Google Scholar][Crossref]
  38. Keelan JA, Mas E, D’Vaz N, D Unstan JA, Li S, Barden AE, et al. Effects of maternal n-3 fatty acids Supplementationon placental cytokines, pro resolving lipid mediators and their precursors. Reproduction. 2015; 149:171-8. [Google Scholar][Crossref]
  39. Jones ML, Mark PJ, Keelan JA, Barden A, Mas E, Mori TA, et al. Maternal dietary Omega3 fatty acids intake increases Resolvins and protectin levels in rat placeta. J Lipid Res. 2013; 54:2247-54. [Google Scholar][Crossref]
  40. Rey C, Nadjar A, Buaud B, Vaysee C, Abert A, Pallet V, et al. Resolvins D1, and E1 promote Resolution of inflammation in microglial cells in vitro. Brain Bhav Immun. 2016; 55:249-59. [Google Scholar][Crossref]
  41. Salas- Hernandez A, Espinoza Perez C, Vivar R, Espitia -Corredor J, Lillo J, Parra Flores P, et al. Resolvins D1, and E1 promote promote resolution of inflammation in rat cardiac fibroblast in vitro. Mol BiolRep. 2021; 48:57-66. [Google Scholar][Crossref]
  42. Weiss GA, Troxler H, Klinke G, Roger G, Braegger C, Hersberger M. High levels of antiinflammatory and proresolving lipid mediators lipoxins and resolvins and declining docosahexaenoic acid levels in human milk during the first month of lactation. Lipids Health Dis. 2013; 12:89. [Google Scholar][Crossref]
  43. Armardottir H, Orr SK, Dalli J, Serhan CN. Human milk proresolving mediators stimulate resolution of acute inflammation. Mucosal Immunol. 2016; 9:757-66. [Google Scholar][Crossref]
  44. Yamashita A, Kawana K, Tomio K, Arita M, Taguchi A, Isobe Y, et al. Increased levels of Omega3 polyunsaturated fatty acids prevents pathological preterm birth. Sci. Rep. 2013; 3:3113. [Google Scholar][Crossref]
  45. Connor KM, San Giovanni JP, Lofqvist C, Aderman International Journal of Medical and All Body Health Research www.allmedicaljournal.com CM, Chen J, Higuchi A, et al. Increased dietary intake of Omega3 polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med. 2007; 13:868-73. [Google Scholar][Crossref]
  46. Hesselink JM, Chiosi F, Costagliola C. Resolvins and alamides: Lipid autacoids in ophthalmology-what promise do they hold? Drug Des Dev Ther. 2016; 10:3133-41. [Google Scholar][Crossref]
  47. Nordgren TM, Anderson Berry A, Van Ormer M, Zoucha S, Elliott E, Johnson R, et al. Omega3 fatty acids Supplementation, pro resolving mediators and Clinical outcomes in maternal infant pairs. Nutrients. 2019; 11:98. [Google Scholar][Crossref]
  48. Aung MT, Yu Y, Ferguson KK, Cantonwine DE, Zeng L, McElrath TF, et al. Prediction and associations of preterm birth and its subtypes with eicosanoid enzymatic pathways and inflammatory markers. Sci Rep. 2019; 9:17049. [Google Scholar][Crossref]
  49. Perucci LO, de Castro Pinto KM, da Silva SPG, Lage EM, Teixra PG, Barbosa AS, et al. longitudinal assessment of leukotrieneB4,lipoxin A4 and resolvin D1 Plasma levels with risk factors for preeclampsia. Clin Bio-chem. 2021; 98:24-8. [Google Scholar][Crossref]
  50. Titos E, Rius B, Lopez Vicario C, Alcarez Quiles J, Garcia Alonso V, Lopategi A, et al. Signaling and immunoresolving actions of resolvin D1 in inflammed visceral adipose tissue. J Immunol. 2016; 197:3360-70. [Google Scholar][Crossref]
  51. Schwab JM, Chiang N, Arita M, Serhan CN. ResolvinE1 and protectin D1 activate inflammation Resolution programmes. Nature. 2007; 447:869-74. [Google Scholar][Crossref]
  52. Pal A, Cowdy KM, Oestreich KJ, Beck M, Shakh SR. Obesity driven deficiencies of Specialized proresolving mediators may drive adverse outcomes during SARS-CoV2 infection. Front Immunol. 2020; 11:199. [Google Scholar][Crossref]
  53. Alam I, Ng TF, Larbi A. Does inflammation determine whether Obesity is metabolically healthy or unhealthy? The aging perspective. Mediat Inflamm, 2012, 456456. [Google Scholar][Crossref]
  54. Claria I, Dalli J, Yacoubian S, Gao F, Serhan CN. Resolvin D1 and resolvin D2govern local inflammatory tone in obese fat. J Immunol. 2012; 189:2597-2605. [Google Scholar][Crossref]
  55. Rius B, Titos E, Moran Salvador E, Lopez Vicario C, Garcia Alonso V, Gonzalez-Periz A, et al. ResolvinD1 primes the Resolution process initiated bycalorie restriction in Obesity induced Steatohepatitis. FASEB J. 2014; 28:836-48. [Google Scholar][Crossref]
  56. Neuhoer A, Zeyda M, Mascher D, Itariu BK, Murano I, Leitner L, et al. Impaired local production of pro resolving lipid mediators in Obesity and 17HDHA as a potential treatment for Obesityassociated inflammation. Diabetes. 2012; 62:601-5. [Google Scholar][Crossref]
  57. Pascoal LB, Bombassaro B, Ramalho AF, Coope A, Moura RF, Correa DaSilva F, et al. Resolvin RvD2reduces hypothalamic inflammation and rescues mice from diet induced obesity. J Neuroinflammation. 2017; 14:5. [Google Scholar][Crossref]
  58. Menon R, Richardson LS, Lappas MF, et al. Membrane architecture, aging and inflammation in pregnancy and parturition. Placenta. 2019; 79:40-5. [Google Scholar][Crossref]
  59. Levine LD, Holland TL, Kim K, Sjaarda LA, Mumford SJ, Schisterman EF. The role of aspirin and inflammation on reproduction. The EAG eR trial. Can J Physiol Pharmacol. 2019; 97:187-92. [Google Scholar][Crossref]
  60. Shafiq M, Mathad JS, Naik S, Alexander M, Yadana S, Araujo-Pereira M, et al. Association of Maternal inflammation during pregnancy with birth outcomes and infants growth among women with and without HIV in India. JAMA Netw Open. 2021; 4:e2140584. [Google Scholar][Crossref]
  61. Han VX, Patel S, Jones HF, Nielse TC, Mohammed SS, Hofer MJ, et al. Maternal acute and chronic inflammation in pregnancyis associated with common neurodevelopmental disorders: a systematic review. Trans Psychiatry. 2021; 11:71. [Google Scholar][Crossref]
  62. Izquierdo AG, Crujeiras AB, Casaneuva EE, Carreira MC. Leptin Obesity and leptin resistance:where are we 25 years later? Nutrients. 2019; 11:2704. [Google Scholar][Crossref]
  63. Moynihan AT, Hehir MP, Glavey SV, Smith TJ, Morrison JJ. Inhibitory effects of leptin on human uterine contractility. Am JObstet Gynaecol. 2006; 195:504-9. [Google Scholar][Crossref]
  64. Morshedzadeh N, Saedisomoelia A, Djalali M, Eshraghian MR, Hantoushzadeh S, Mahmoudi M. resolvin D1 impacts on insulin resistance in women with Polycystic ovary syndrome and healthy women. Diabetes Metab Syndr. 2019; 13:660-4. [Google Scholar][Crossref]
  65. White PJ, Arita M, Taguchi R, Kang JX, Marette A. Transgenic restoration of long chain n3 fatty acids in insulin target tissues improves resolution capacity and alleviates Obesity linked inflammation and insulin resistance in high fat fed mice. Diabetes. 2010; 59:3066-73. [Google Scholar][Crossref]
  66. Echeverria F, Valenzuela R, Espinosa A, Bustamante A, Alvarez D, Gonzalez-Mana D, et al. Reduction of high fat induced liver proinflammatory state by eicosapentaenoic acid plus hydroxyl sterol supplementation: involvement of resolvinRvE1/ E2 and RvD1/2. J Nutr Biochem. 2019; 63:35-43. [Google Scholar][Crossref]
  67. Lopez Vicario C, Titos E, Walker ME, Alcarez Quiles J, Casulleras M, Duran Guell M, et al. Leukocyte from Obese individuals exhibit an impaired SPMsignature. FASEB J. 2019; 33:7072-83. [Google Scholar][Crossref]
  68. Bashir S, Sharma Y, Jairajpuri D, Rashid F, Nematullah M, Khan F. Alterations of adipose tissue immune cell milieu towards suppression of inflammation in high fat fed micebyflaxweed supplementation. PLo SONE. 2019; 14:e0223070. [Google Scholar][Crossref]
  69. Kosaraju R, Guesdon W, Crouch MJ, Teague HL, Sullivan EM, Karlsson EA, et al. B cell activity is impaired in human and mouse Obesity and is responsive to essential fatty acid upon murinei influenza infection. J Immunol. 2017; 198:4738-52. [Google Scholar][Crossref]
  70. Petrakis D, Margina D, Tsarouhas K, Tekos F, Stan M, Nikitovic D, et al. Obesity-a risk factorfor increased COVID19 Prevalence, severity and lethality (review). Mol Med Rep. 2020; 22:9-19. [Google Scholar][Crossref]
  71. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. LICORN and the Lille COVID19 and Obesity study group. High Prevalence of Obesity severe respiratory distress syndrome Coronavirus 2 (SARS-CoV2) requiring invasive mechanical ventilation. Obesity. 2020; 28:1195-9. [Google Scholar][Crossref]
  72. Liu M, He P, Liu HG, Wang XJ, Li FJ, Chen S, et al. Clinical characteristics of 30 medical workers infected with new Coronavirus Pneumonia. Zhongua Jie He He Hu Xi Za Zhi. 2020; 43:E016. [Google Scholar][Crossref]
  73. Peng YD, Meng K,Guan HQ, Leng L, Zhu RR, Wang BY, et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019n CoV. Zhongua Jie He He Hu Xi Za Zhi. 2020; 48:450-5. [Google Scholar][Crossref]
  74. Lighter J, Phillips M, Hochman S, Sterling S, Jiohnson International Journal of Medical and All Body Health Research www.allmedicaljournal.com D, Francois F, et al. Obesity in in patients younger than 60years isa a risk factor for COVID19 hospital admission. Clin Infect Dis. 2020; 71:896-7. [Google Scholar][Crossref]
  75. Costela-Ruiz VJ, Ilescas Montes R, Puerta Puerta JM, Ruis C, Melguizo Rodriques-L, et al. SARS-CoV2 infection:the role of cytokines in COVID19 disease. Cytokine Growth Factor Rev. 2020; 54:62-75. [Google Scholar][Crossref]
  76. Neuzil KM, Reed GW, Mitchell EF, Simonsen L, Griffin MR. Impact of influenza infection on acute cardiopulmonary hospitalization. Am J Epidemiol 1998; 148:1094-1102. [Google Scholar][Crossref]
  77. Kraus TA, Engel SM, Sperling RS, Kekkerman L, Lo Y, Wallenstein S, et al. Characteristizing the pregnancy immune phenotype: results of the viral immunity and pregnancy(VIP). J Clin Immunol. 2012;32:300-11. [Google Scholar][Crossref]
  78. Wegmann TG, Lin H, Guilbert L, Mosmann TR. bidirectionalcytokines in the Maternal-Fetal relationship? is successful pregnancy aTh2 phenomenon. Immunol Today. 1993; 14:353-6. [Google Scholar][Crossref]
  79. Klein SL, Passaretti C, Anker M, Olukoya A, Pekosz A. The Impact of sex, gender and pregnancy on 2009 H1N1. Biol Sex Differ. 2010; 1:5. [Google Scholar][Crossref]
  80. Stockman LJ, Lowther SA, Coy K, Saw J, Parashar UD. SARS during pregnancy, United States. Emeg Infect Dis. 2004; 10:1689-90. [Google Scholar][Crossref]
  81. Khalil A, Kalafat E, Benliogl CO, Brien P, Morris E, Draycott T, et al. SARS-CoV2 infection inpregnanc:a systematic review and meta-analysis of Clinical features and pregnancy outcomes. E Clinical Medicine. 2020; 25:100446. [Google Scholar][Crossref]
  82. Panagiotakopoulos L, Myers TR, Gee J, Lipkind HS, Kjarbanda EO, Ryan DS, et al. SARS-CoV2 infection among hospitalized patients: reasons for admission and pregnancy characteristics-eight US health care centres, 1march-may302020.MMWR Morb Mort Wkly Rep. 2020; 69:1355-59. [Google Scholar][Crossref]
  83. Lapolla A, Dalfra MG, Burlina S. Vaccination against COVID19 infection: the need for evidence for diabetic and obese pregnant women. Acta Diabetol 2021; 58:1581-5. [Google Scholar][Crossref]
  84. Nordgren TM, Lyden E, Anderson Berry A, Hanson C. Omega3 fatty acids intake of pregnant women and women of childbearing age in the United States: potential for deficiency? Nutrients. 2017; 9:197. [Google Scholar][Crossref]
  85. Jandacek RJ. Linoleic acid: A nutritional quandary. Healthcare. 2017; 5:25. [Google Scholar][Crossref]
  86. Marchix J, Catherine D, Duby C, Monthean Bpolier N, Boisel F, Pedrono F, et al. Interactive effects of Maternal and weaning high Linoleic acid intake on hepatic lipid metabolism, oxylipins profile and hepatic steatosis in offspring. J Nutr J Biochem. 2020; 75:108241. [Google Scholar][Crossref]
  87. Suratt BT, Ubags NDJ, Rastogi D, Tantisira KG, Marsland BJ, Petrache J, et al. Allergy, Immunology and inflammation assembly. An Official American Thoracic Society Workshop report: Obesity and metabolism: an emerging Frontier in lung Health and disease. Ann Am Thorac Soc. 2017; 14:1050-9. [Google Scholar][Crossref]
  88. Souza PR, Marques RM, Gomez EA, Colas RA, DeMatties R, Zak A, et al. Enriched marine oil Supplements increase peripheral blood Specialized proresolving mediators Concentration and Reprogram host immune responses:a randomized, double blind, placebo controlled study. Circ Res. 2020; 126:75-90. [Google Scholar][Crossref]
  89. Quiros M, Feier D, Birki D, Agarwal R, Zhou DW, Garcia AJ, et al. Resolvin E1 is a prorepair molecule that promotes intestinal epithelial wound healing. Proc NatlAcad Sci USA. 2020; 117:9477-82. [Google Scholar][Crossref]
  90. Pal A, Al Shaeer AE, Guesdon W, Torres MJ, Armstrong M, et al. Resolvin E1, derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic manner. FASEB J. 2020; 34:10640-56. [Google Scholar][Crossref]
  91. Fanos V, Atzori L, Makare nko K, Melis GB, Ferrazi E. Metabolomics application in Maternal-Fetal medicine. Biomed Res Int. 2013; 2013:720514. [Google Scholar][Crossref]
  92. Fanos V, Antonucci R, Barberini L, Noto A. Clinical application of metabolomics in neonatology. J Maternal Fetal Neonatal Med. 2012; 25(Suppl 1):104-9. [Google Scholar][Crossref]

How to Cite

Kaur, K. K., Allahbadia, G. N. K., & Singh, M. (2022). An Innovative Approach of Escalating Maternal Fetal Outcomes in Pregnancies associated with Obesity: Overcoming Deficiency of Resolvins associated with Obesity: A Systematic Review. International Journal of Medical and All Body Health Research, 3(4), 03-13.

Kaur, Kulvinder Kochar, et al. "An Innovative Approach of Escalating Maternal Fetal Outcomes in Pregnancies associated with Obesity: Overcoming Deficiency of Resolvins associated with Obesity: A Systematic Review." International Journal of Medical and All Body Health Research, vol. 3, no. 4, 2022, pp. 03-13.

Kaur, K. K., Allahbadia, G. N. K. and Singh, M. (2022) 'An Innovative Approach of Escalating Maternal Fetal Outcomes in Pregnancies associated with Obesity: Overcoming Deficiency of Resolvins associated with Obesity: A Systematic Review', International Journal of Medical and All Body Health Research, 3(4), pp. 03-13.

Kaur KK, Allahbadia GNK, Singh M. An Innovative Approach of Escalating Maternal Fetal Outcomes in Pregnancies associated with Obesity: Overcoming Deficiency of Resolvins associated with Obesity: A Systematic Review. International Journal of Medical and All Body Health Research. 2022;3(4):03-13.

Share

Find this Article on

Google Scholar Semantic Scholar OpenAlex ResearchGate BASE

A newly published article may take a few days to appear on these services.